These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28707314)

  • 1. Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience.
    Gemici A; Aydogdu I; Terzi H; Sencan M; Aslan A; Kaya AH; Dal MS; Akay MO; Dogu MH; Ayyildiz O; Sahin F; Cagliyan GA; Yilmaz M; Gokgoz Z; Bilen Y; Demir C; Sevindik OG; Korkmaz S; Eser B; Altuntas F;
    Hematol Oncol; 2018 Feb; 36(1):116-120. PubMed ID: 28707314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nodular lymphocyte predominant Hodgkin's lymphoma.
    Siddiqui N; Al-Diab AI
    Saudi Med J; 2005 Feb; 26(2):241-5. PubMed ID: 15770298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
    Mocikova H; Pytlik R; Stepankova P; Michalka J; Markova J; Koren J; Buresova L; Raida L; Kral Z
    Acta Haematol; 2015; 134(3):187-92. PubMed ID: 26021284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
    Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
    Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nodular lymphocyte-predominant Hodgkin's lymphoma: Principles of diagnosis and treatment].
    Moiseeva TN; Al-Radi LS; Kovrigina AM; Goryacheva SR; Julakyan UL; Margolin OV; Skidan NI; Tseytlina MA; Kravchenko SK
    Ter Arkh; 2015; 87(11):78-83. PubMed ID: 26821421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
    Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
    Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East.
    Akhtar S; Rauf MS; Khafaga Y; Al-Kofide A; Elhassan TAM; Elshenawy MA; Nadri J; Mushtaq AH; Bakshi N; Shamayel M; Al-Sweedan S; Sarwar S; Maghfoor I
    BMC Cancer; 2021 Apr; 21(1):351. PubMed ID: 33794818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.
    Al-Mansour M; Connors JM; Gascoyne RD; Skinnider B; Savage KJ
    J Clin Oncol; 2010 Feb; 28(5):793-9. PubMed ID: 20048177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
    Strati P; Cheng PTM; Steiner RE; Alcedo Andrade PE; Feng L; Sano D; Rao VA; Singh P; Miranda R; Gunther JR; Pinnix CC; Dabaja BS; Cuglievan B; Xing K; Villa D; Skinnider B; Sehn LH; Connors JM; Nieto Y; Ahmed S; Lee HJ; Savage KJ
    Br J Haematol; 2021 Feb; 192(3):560-567. PubMed ID: 33517581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
    Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
    J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India.
    Prasad M; Narula G; Chinnaswamy G; Arora B; Shet T; Panjwani P; Sengar M; Laskar S; Khanna N; Banavali S
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27288. PubMed ID: 29893471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
    Biasoli I; Stamatoullas A; Meignin V; Delmer A; Reman O; Morschhauser F; Coiffier B; Bosly A; Diviné M; Brice P
    Cancer; 2010 Feb; 116(3):631-9. PubMed ID: 20029973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
    Olszewski AJ; Shrestha R; Cook NM
    Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.
    Bodis S; Kraus MD; Pinkus G; Silver B; Kadin ME; Canellos GP; Shulman LN; Tarbell NJ; Mauch PM
    J Clin Oncol; 1997 Sep; 15(9):3060-6. PubMed ID: 9294468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.